Key facts
- This page summarizes Jeff E. Knight's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Mar 2025, 18:33.
Jeff E. Knight - 19 Mar 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- CRNX
- Reported as of
- 19 Mar 2025
- Net transaction value
- -$244,964
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2025, 18:33:31 UTC
- Prior SEC filing
- 24 Feb 2025
- Next SEC filing
- 25 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- Tobin Schilke, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeff E. Knight filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 21 Mar 2025.
Change
- Previous filing in this sequence was filed on 24 Feb 2025.
- Current net transaction value: -$244,964.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Sale
- Transaction value
- $232,390
- Shares
- -6,801
- Change %
- -7.2%
- Price
- $34.17
- Shares after
- 87,852
- Date
- 19 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
CRNX
transaction
Common Stock
Sale
- Transaction value
- $12,574
- Shares
- -361
- Change %
- -0.41%
- Price
- $34.83
- Shares after
- 87,491
- Date
- 19 Mar 2025
- Ownership
- Direct
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
Footnote F2
The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Footnote F3
Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
Footnote F4
The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.